Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chimpanzees chronically infected with hepatitis-B virus showed transient changes in several markers of infection when treated with the interferon inducer polyriboinosinic-polyribocytidylic acid-poly-l-lysine carboxymethyl cellulose. Serum Dane-particle-associated D.N.A. polymerase, e antigen and hepatitis-B surface antigen, and intrahepatic hepatitis-B surface and core antigens diminished during treatment. Defective (D.N.A.-polymerase-negative) Dane particles increased in titre transiently during treatment; these may play a role in the modulation of hepatitis-B virus infection. Humoral immune responses in chronic hepatitis-B carrier chimps were unaffected. Interferon inducers (or exogenous interferon) may be useful for the treatment of chronic hepatitis-B virus infection.
 ...
PMID:Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. 6 40

A new antigen antibody system the e Ag and Ab has been investigated by immunodiffusion and counterelectrophoresis in the serum of 509 subjects. Those included 242 patients with polyarteritis, acute chronic or fulminant hepatitis; 85 hemodialysis HBs Ag carriers and 182 asymptomatic HBs Ag carrier blood donors. Neither e Ag nor anti- e were detected in any of the non hepatitis B virus associated cases. Counterelectrophoresis was found to be more sensitive than immunodiffusion and detected either e Ag or anti- e in 24 p. cent more cases. e Ag was found among HBs Ag positive patients with polyarteritis, chronic hepatitis or under going hemodialysis. Anti- e was observed in 28 p. cent to 66 p. cent of asymptomatic HBs Ag carriers. The study of the nature and prognostic significance of e Ag and anti- e appear of major importance in the understanding and follow up of HB virus infections.
 ...
PMID:[Detection and prognostic significance of Ag "e" and its antibody in the course of HB virus infections[]. 6 79

Lymphocyte cytotoxicity for isolated hepatocytes has been demonstrated in 93% of cases of acute viral hepatitis tested within two weeks of the onset of symptoms. The frequency of cytotoxicity during this time was similar for HBsAg positive and negative cases. However, after this time it was significantly higher in HBsAg positive than negative cases, 90% and 25% respectively (P less than 0-01). Cytotoxicity was found in B-cell, but not T-cell, enriched fractions of lymphocytes, compatible with an antibody-dependent K-cell mediated reaction. In two cases the assay remained positive on retesting six months later, and follow-up liver biopsies showed the features of chronic aggressive hepatitis. These findings suggest that, in addition to the known immunological reactions against viral antigens that occur during the acute phase of viral hepatitis, an autoimmune reaction directed against a liver specific protein is also initiated; and if this reaction persists then chronic hepatitis may develop.
 ...
PMID:Autoimmune reaction to a liver specific membrane antigen during acute viral hepatitis. 6 5

Hypersensitivity of a delayed type to leukocyte hepatitis virus (LHV) was established in patients with virus hepatitis. The results of the skin tests with the LHV antigen were positive in 15 out of 20 patients with active chronic hepatitis, in 17 out of 20 convalescents and in 3 out of 20 patients in the acute stage of virus hepatitis, and negative in 4 normal subjects and in 12 out of 14 patients with chronic hepatitis in the stage of stabilization. The results of the skin tests with the antigen of donor leukocytes were negative in 130 patients with hepatitis and normal subjects. In the leukocyte migration inhibition test, 1/4 of the patients with chronic hepatitis were found to be sensitized to the LHV antigen, in the absence of sensitization by this test to the HB antigen and the antigen in the plasma of hepatitis patient.
 ...
PMID:[Cellular immunity responses in studies of the specificity of leukocyte hepatitis virus]. 6 28

The e determinant of hepatitis B surface antigen (HBS Ag) was found in 23 of 42 patients with chronic hepatitis B virus (HBV) infection. Presence of e antigen was associated with increases in DNA polymerase activity and in the number of circulating Dane particles. In the group with detectable e antigen, the average DNA polymerase activity was 367+/-78 counts per minute (cpm; mean+/-standard error [SE]), and the average number of Dane particles counted in electron micrographs was 4.4% of the total HBS Ag. In contrast, e antigen-negative patients had an average DNA polymerase activity of 40+/-6.9 cpm (P less than 0.1) and an average Dane particle count equal to 0.6% of the HBS Ag. The e antigen was detected in 68% of patients who were HBS Ag carriers or had persistent viral hepatitis and 40% of those with chronic active type B hepatitis. Thus, the presence of e antigen correlated with both the chronicity and presence of infectious HBV. However, it did not correlate with the type or severity of liver disease after HBV infection, since e antigen was present in both chronic benign and chronic aggressive hepatitis B infections.
 ...
PMID:Correlation of e antigen, DNA polymerase activity, and Dane particles in chronic benign and chronic active type B hepatitis infections. 6 88

The prognostic significance of in-vitro complement fixation (V.C.F.) by hepatitis-B core antigen/antibody immunocomplexes in hepatitis-B surface antigen (HBsAg) positive liver biopsy specimens was prospectively evaluated in 47 patients presenting with acute viral hepatitis type B. 34 of 37 V.C.F.-negative patients made an uneventful recovery and became HBsAg negative; in all patients with a V.C.F.-positive test chronic hepatitis and persistent antigenaemia developed. The V.C.F. test is a simple and reliable prognostic indicator of persistent infection and of progression of apparently acute hepatitis to a chronic liver disorder.
 ...
PMID:Prognostic significance of in-vitro complement fixation in liver biopsy specimens from patients with acute viral hepatitis type B. 7 41

Serial determinations of HBeAg and anti-HBe were made in sera of 155 selected patients with acute hepatitis B who were followed up for one to four years. In the early phase of hepatitis, HBeAg was present in 43 cases (27.7%) and anti-HBe in 12 cases (7.7%). Evaluation of the outcome of hepatitis showed that development of chronic hepatitis occurred in 11 out of 43 HBeAg positive patients, in 10 out of 100 HBeAg negative patients (P = less than 0.05) and in 2 out of 12 patients carrying anti-HBe. Nine out of 11 HBeAg positive chronic subjects showed persistent HBe antigenemia over two months, while the remaining 32 patients, who recovered completely, lost HBeAg within two to three weeks from the onset of the disease. These data suggest that the prognostic value of HBeAg in acute hepatitis patients may be taken into account when HBeAg persists in the serum and that anti-HBe does not invariably protect from the development of chronic hepatitis.
 ...
PMID:Persistence of e antigen as prognostic marker in acute hepatitis B. 8 94

Cellular and humoral immunity combine to determine the outcome following exposure to hepatitis virus and are implicated in the proposed pathogenetic mechanism for acute and chronic hepatitis. Although antibody to HBsAg is found in virtually all following recovery from hepatitis B, a cell-mediated response to HBsAg can be detected in most patients during the acute phase, and it has been suggested that this may cause the acute hepatic damage by an attack on virus-infected cells. Patients who have chronic active hepatitis also frequently have cell-mediated immunity to HBsAg, regardless of whether the antigen can be detected in their sera; thus, previous exposure to hepatitis B may be important in initiating the disease even in antigen-negative cases. Cell-mediated responses to liver-specific lipoprotein, a membrane antigen, occur transiently in many patients who have acute hepatitis and are persistent in virtually all with untreated chronic active hepatitis. The relative importances and precise mechanisms of these immune responses in the pathogenesis of acute and chronic hepatitis remain to be determined.
 ...
PMID:Cellular and humoral immunity in viral hepatitis. 8 10

To clarify the aetiology of an outbreak of HBsAg-negative acute hepatitis in the renal unit at Fulham Hospital in 1968--70, serological tests for antibody to hepatitis-A virus (anti-H.A.V.) were done retrospectively on serum samples obtained at the time of the outbreak. 7 patients had had two previous episodes of clinical HBsAg-negative hepatitis. Serum samples were available from 24 of the 29 infected patients, and these were paired in 12 instances. There was a slight increase in the titre of anti-H.A.V. in 1 patient, and a further 2 patients who subsequently developed chronic hepatitis showed a decrease in titre, but no changes in titre were detected in the remaining 21 cases. These findings do not provide evidence for the involvement of hepatitis-A virus in the outbreak of hepatitis and effectively exclude a role for this virus in the chrnoic liver disease which developed subsequently in 8 (28%) of the patients. This outbreak is therefore probably non-A non-B hepatitis, which has not been reported previously in Great Britain in a haemodialysis unit. The results confirm that this form of hepatitis may be related to a high frequency of persistent hepatic dysfunction.
 ...
PMID:Non-A non-B hepatitis associated with chronic liver disease in a haemodialysis unit. 8 18

A microtitre solid-phase blocking radioimmunoassay (RIA) for antibody to the hepatitis B virus (HBV)-associated delta antigen was specific and detected anti-delta antibody at dilutions of serum of up to 10(6). Analysis of sera from HBsAg-negative subjects and different categories of HBsAg carriers from different regions confirmed the association of anti-delta antibody with HBV infection. Anti-delta antibody was detected in persistently high titres in 19.1% and 2.6% of sera from patients with chronic hepatitis and symptomatic chronic carriers, respectively, and was not detected in the sera of HBsAg-negative controls. Anti-delta antibody appeared transiently and in low titres (less than 1:500) in 4.8% of sera from patients with acute type B hepatitis. The presence and persistence of anti-delta antibody seem to be associated with chronic HBV infection and the development of progressive liver damage.
 ...
PMID:Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. 9 76


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>